According to a new research report “β-Site Aβ Cleaving Enzyme or Beta-Secretase (BACE) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments” published by Pharma Proff, BACE inhibitors currently exhibit a proliferating pipeline with 15+ therapeutic candidates.
BACE Inhibitors Pipeline Insights
BACE is a cleaving enzyme that acts as a precursor of BACE α-amyloid (Aβ) protein generation. It possesses BACE α-secretase activity and is important for the formation of myelin sheaths in peripheral nerve cells. BACE can be classified into BACE1 and BACE2. BACE1 is an aspartic protease, which utilizes an aspartate residue for the substrate catalysis; whereas, BACE2 is a homologue of BACE1.
Moreover, BACE primarily breakdown amyloid precursor protein (APP) into APPβ and C99. C99 is further cleaved by γ-secretase forming Aβ1-40 and Aβ1-42. The inhibition of BACE activity terminates the formation of Aβ, thereby preventing the damage of brain cells.
Insights into Pipeline Segments
According to research findings, majority of drug candidates in pipeline are being developed to be administered through intravenous route. It has been observed that the intravenous route of medication is convenient and provides improved patient’s compliance. Administration of therapeutics through this route has shown promising results in clinical studies.
Positive Clinical Results Play a Pivotal Role in BACE Inhibitors Development
There are several companies that are involved in developing BACE inhibitors have shown positive clinical results in various phases of drug development. For instance, in July 2018, Eisai Co. Ltd. and Biogen Inc. announced positive top-line data of BAN2401’s Phase II trials, which demonstrated that BAN2401 statistically slowdown disease progression after 18 months of the trial. The drug was safe and well-tolerated in patients suffering from Alzheimer's disease (AD).
Browse report overview with detailed TOC on "β-Site Aβ Cleaving Enzyme or Beta-Secretase (BACE) Inhibitors – Pipeline Analysis 2019, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments" at:https://www.pharmaproff.com/report/beta-secretase-inhibitors-pipeline-analysis
BACE Inhibitors Pipeline Analysis
The report comprises detailed pipeline analysis of BACE inhibitors under development. Comprehensive insights on the pipeline products have been provided, with special focus on strategic developments of key players, information on drug licensing, designations, financing, and grants, technological advancements, patents, and upcoming conferences. In addition, the report highlights the winning strategies of companies involved in the development of BACE inhibitors. Detailed regulatory approval procedures in the U.S., Europe, and Japan are also provided in this report. Furthermore, the report contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanisms of action, and drug origin with respect to BACE inhibitors.